Genmab — Marts 2023

[StockBull]

Morn, Stærkt signal som støtter casen op til q1 regnskab 10 maj og Epcoritamab PDUFA 21 maj. Derefter ASCO konferencen 2023 2-6 juni. Kommer vel også snart H2H data mod Darzalex. https://www.proinvestor.com/boards/111617/$/111666

[bibob]

Gode artikler fra OncLive. https://www.onclive.com/effective-utilization-of-cd38-agents-imids-spur-further-clinical-research-in-relapsed-refractory-myeloma

[bibob]

https://www.onclive.com/view/daratumumab-based-quadruplet-therapy-demonstrates-mrd-negativity-benefit-in-newly-diagnosed-myeloma?utm_source=sfmc&utm_medium=email&utm_campaign=03242023_OncLive_SAN-23-OSD1504_GLOBAL MM Condition Center_Sanofi Sarclisa_Global - Denmark&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[bibob]

https://www.onclive.com/view/unmet-needs-and-future-perspectives-in-multiple-myeloma-care?utm_source=sfmc&utm_medium=email&utm_campaign=03242023_OncLive_SAN-23-OSD1504_GLOBAL MM Condition Center_Sanofi Sarclisa_Global - Denmark&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[E_L]

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial

[E_L]

BioNTech Fourth Quarter and Full Year 2022 Earnings Presentation https://investors.biontech.de/events/event-details/2022-q4-and-full-year-earnings-call

[Hamming]

https://twitter.com/BertrandBio/status/1640308983717134336

[bikube]

Det nærmer sig slutningen på opkøb af egne aktier, de mangler lige at købe de sidste 25 K aktier i løbet af ugen.

[ProinvestorNEWS]

Transactions in connection with share buy-back program https://www.proinvestor.com/investornyt/960086/transactions-in-connection-with-share-buy-back-program

[peter12]

Jeg spurgte chatgpt om bnt322. Tror ikke den er helt gal på den : The two companies plan to use Biontech's innovative mRNA technology platform to develop a new class of antibody therapeutics targeting solid tumors. BNT322 is designed to selectively destroy cancer cells by engaging the immune system in a highly specific manner

[E_L]

Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer https://ir.genmab.com/news-releases/news-release-details/genmab-announces-appointment-martine-van-vugt-chief-strategy

[E_L]

epcoritamab on the CHMP agenda this week to discuss responses received to Day 120 List of Questions

[SEACOP]

Er der nogen naturlig arvtager (kronprins/prinsesse), som blot rager lidt op?

[StockBull]

JNJ, AbbVie,

[StockBull]

The M&A hunt is on — here are the prime targets

Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

PharmaVoice (www.pharmavoice.com)

[bikube]

Sanofi proposed to acquire Provention Bio for $2,9B in cash at 273% premium.

[royal]

Har Abbvie råd til at købe Genmab?

[troldmanden]

Tror ikke lige Amanda er så heldig med den "liste" over opkøbs kandidater. Altimmune har lige præsenteret data. Fint vægtab på ca 10%. Men "Most patients experienced nausea and vomiting of mild and moderate severity"

[StockBull]

Ja, AbbVie (ABBV) står over for et af de stejleste patentfrafald i branchen, når Humira mister sin amerikanske eksklusivitet næste år. Analytikere forventer, at virksomheden vil have 69 milliarder dollars i frit cash flow frem til 2024 for at genopbygge sine hylder. Andre firmaer, der forventes at se høje kontanter, er Roche, Bristol Myers og Merck.

[Sukkeralf]

Pfizer